Residency · Residency · Preventive Medicine

Precision Public Health: Genomics Meets Population Health

Introduction

Precision public health applies granular data -- including genomics, geospatial data, environmental exposures, and individual-level health information -- to target preventive interventions to the right populations at the right time. Extends the concept of precision medicine from individual clinical care to population-level disease prevention and health promotion. The integration of genomics into public health practice has progressed from newborn screening to pharmacogenomics, cascade screening, and population-level risk stratification. Precision public health maintains the population perspective while leveraging individual-level data to improve intervention effectiveness and efficiency.

Genomics in Public Health

Spectrum of Genetic Influence on Disease

Monogenic (Mendelian) disorders: Single gene mutations with high penetrance (e.g., sickle cell disease, cystic fibrosis, Huntington disease); rare individually but collectively affect millions. High-penetrance cancer susceptibility genes: BRCA1/2 (breast/ovarian cancer), Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2) for colorectal and endometrial cancer; APC (familial adenomatous polyposis) Common complex diseases: Influenced by many genetic variants of small effect interacting with environmental factors (diabetes, cardiovascular disease, most cancers); polygenic risk scores aggregate these effects. Pharmacogenomics: Genetic variation affecting drug metabolism, efficacy, and adverse reactions (CYP2D6, CYP2C19, HLA-B*5701, DPYD)

Population-Level Genomic Programs

Newborn screening: The oldest and most established precision public health program; all 50 states screen for 30-50+ conditions using the Recommended Uniform Screening Panel (RUSP). Conditions include phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and an expanding panel of metabolic and genetic disorders. CDC Tier 1 genomic applications: Evidence-based genomic applications with significant potential for population health impact. Hereditary breast and ovarian cancer (HBOC): BRCA1/2 testing for individuals meeting criteria; cascade testing of family members. Lynch syndrome: Universal tumor screening for mismatch repair deficiency in all colorectal cancers; cascade testing of relatives. Familial hypercholesterolemia (FH): Affects 1 in 250 people; cascade screening identifies individuals at 20-fold increased risk of premature coronary artery disease.

<image>Pyramid diagram showing the spectrum of genomic applications in public health, from established programs at the base (newborn screening, family history assessment) through emerging applications in the middle (pharmacogenomics implementation, CDC Tier 1 conditions, population-based carrier screening) to frontier applications at the top (polygenic risk scores for common diseases, whole genome sequencing in public health), with evidence level and implementation readiness indicated for each tier</image>

Polygenic Risk Scores

Concept and Development

Polygenic risk scores (PRS) aggregate the effects of hundreds to millions of common genetic variants to estimate an individual's genetic predisposition to a disease. PRS are calculated by summing risk alleles weighted by their effect sizes from genome-wide association studies (GWAS). PRS can identify individuals at the tails of the risk distribution whose genetic risk approximates that of monogenic conditions (e.g., top 1-5% PRS for CAD may have risk comparable to familial hypercholesterolemia)

Clinical and Population Health Applications

Coronary artery disease: PRS can reclassify individuals into higher or lower risk categories beyond traditional risk factors; may inform statin initiation decisions. Breast cancer: PRS combined with clinical risk factors (family history, reproductive history, mammographic density) can refine screening recommendations. Type 2 diabetes: PRS identifies high-risk individuals who may benefit from intensive lifestyle intervention. Prostate cancer: PRS may inform screening decisions, particularly for men at intermediate clinical risk.

Limitations and Concerns

Ancestry bias: Most GWAS have been conducted in populations of European descent; PRS performance is significantly reduced in non-European populations, risking exacerbation of health disparities. Modest individual-level prediction: PRS explain only a fraction of disease variance; clinical utility for individual prediction remains limited for most conditions. Ethical concerns: Genetic determinism, psychological impact of risk information, potential for discrimination, and direct-to-consumer testing without adequate counseling. Implementation challenges: Integration into clinical workflows, genetic counseling capacity, and health system readiness.

Precision Approaches to Infectious Disease

Pathogen Genomics

Whole genome sequencing (WGS) of pathogens has transformed outbreak investigation, replacing pulsed-field gel electrophoresis (PFGE) for foodborne illness and standard genotyping for TB. PulseNet and the Pathogen Detection system use WGS to identify clusters and trace outbreaks of foodborne illness in real-time. SARS-CoV-2 genomic surveillance tracked viral evolution, identified variants of concern, and informed public health response through platforms like GISAID and CDC's National SARS-CoV-2 Strain Surveillance. WGS-based antimicrobial resistance profiling enables targeted treatment and resistance surveillance.

Wastewater Genomics

Wastewater-based epidemiology uses genomic analysis of sewage to detect population-level circulation of pathogens (SARS-CoV-2, polio, influenza, mpox) Provides earlier signal than clinical surveillance and captures asymptomatic and untested infections. Successfully deployed during COVID-19 to monitor community transmission trends and detect new variants.

<image>Infographic showing precision public health applications across three domains: host genomics (newborn screening, BRCA testing, pharmacogenomics, polygenic risk scores), pathogen genomics (whole genome sequencing for outbreak investigation, antimicrobial resistance surveillance, variant tracking), and environmental/geospatial precision (wastewater surveillance, environmental exposure mapping, precision targeting of interventions), with examples and data sources for each domain</image>

Geospatial and Environmental Precision

Geographic information systems (GIS) enable spatial analysis of disease patterns, environmental exposures, and healthcare access at granular levels. Precision targeting of preventive interventions: identifying specific neighborhoods, schools, or workplaces for vaccination campaigns, lead screening, or chronic disease programs. Environmental monitoring: Real-time air quality data, water quality monitoring, and climate data integrated with health outcomes for targeted public health action. Social vulnerability indices: Combining sociodemographic, housing, and healthcare access data to identify populations most at risk during emergencies.

Ethical, Legal, and Social Implications (ELSI)

Genetic discrimination: The Genetic Information Nondiscrimination Act (GINA) prohibits discrimination in employment and health insurance but does not cover life insurance, disability insurance, or long-term care insurance. Health equity: Precision public health must avoid widening disparities by ensuring equitable access to genomic technologies and diverse representation in research. Data privacy and governance: Genomic data requires robust privacy protections; community engagement in data governance is essential, particularly for historically exploited populations. Informed consent: Population-level genomic screening raises questions about consent, incidental findings, and the right not to know. Commercialization: Direct-to-consumer genetic testing (23andMe, AncestryDNA) raises concerns about data privacy, clinical validity, and unregulated health risk information.

Key Clinical Pearls

CDC Tier 1 genomic applications (HBOC, Lynch syndrome, FH) have the strongest evidence base for population health impact and should be systematically implemented in preventive medicine practice. Polygenic risk scores are not yet ready for routine population-level screening due to limited predictive value, ancestry bias, and implementation challenges, but they are increasingly used in research and select clinical settings. Pathogen whole genome sequencing has already transformed public health practice in outbreak investigation and antimicrobial resistance surveillance. Precision public health must be developed with explicit attention to health equity to avoid creating a genomic divide that benefits only well-resourced, well-represented populations.

References

1. Khoury MJ, Iademarco MF, Riley WT. Precision public health for the era of precision medicine. Am J Prev Med. 2016;50(3):398-401.
2. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224.
3. Armstrong GL, MacCannell DR, Taylor J, et al. Pathogen genomics in public health. N Engl J Med. 2019;381(26):2569-2580.
4. Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591.

Read this lecture as Markdown